Mark Sullivan, Founder and CEO of Medicines Development for Global Health (MDGH), has been awarded the Officer of the Order of Australia (AO), one of the highest civilian honours in Australia.
January 25, 2022
Mark Sullivan, Managing Director and Founder of Medicines for Global Health, was awarded one of EY Australia's "Entrepreneur of the Year" awards in the social category for his work in establishing MDGH...
November 5, 2019
Awarded annually, the Prix Galien Award recognizes outstanding achievements in improving the global human condition through the development of innovative drugs and other treatments...
July 18, 2019
The award is for his vision in establishing Medicines Development for Global Health to address health inequity, and the novel funding approach that was applied...
May 20, 2019
Fast Company is a highly-regarded magazine based in New York. It is dedicated to the intersection of business, innovation, and design, and engages with the world’s most influential leaders and companies on the future of business...
February 20, 2019
Medicines Development for Global Health (MDGH) is delighted to announce that it has received the 2018 AusBiotech and Johnson & Johnson Innovation Industry Excellence Award in the “Established Company of the Year Award” category.
November 1, 2018
Medicines Development for Global Health Founder and Managing Director Mark Sullivan was named 2019 Victorian Australian of the Year this week for his vision for bringing urgently needed medicines into the fight against Neglected Tropical Diseases.
October 24, 2018
Mark Sullivan, the founder, Managing Director and Board Member of Medicines Development for Global Health, was interviewed by Dr. Norman Swan on today’s Health Report, broadcast nationally in Australia. The interview covers MDGH’s business model, the FDA’s approval of Moxidectin, and the medicine’s potential to help the fight against river blindness, which is a leading global cause of preventable blindness. Click anywhere to listen to a recording on the ABC’s website.
June 18, 2018
Medicines Development for Global Health (MDGH) and the World Health Organisation Special Programme for Research and Training in Tropical Diseases (TDR) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved moxidectin 8 mg oral for the treatment of river blindness (onchocerciasis) in patients aged 12 years and older. The FDA has also awarded MDGH a priority review voucher ....
June 13, 2018